Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Clin Exp Pharmacol Physiol ; 51(3): e13833, 2024 03.
Artigo em Inglês | MEDLINE | ID: mdl-38302079

RESUMO

Previous clinical reports have shown that capecitabine, an oral prodrug of 5-fluorouracil (5-Fu), can induce peripheral neuropathy, resulting in numbness, paresthesia and hypoesthesia. However, the mechanism through which capecitabine causes peripheral nerve injury remains unclear. Here, we demonstrate that systemic administration of capecitabine leads to myelin abnormalities in the peripheral nerves of mice, which are possibly attributed to the death of Schwann cells, the myelinating cells in the peripheral nervous system. Furthermore, our results show that 5-Fu induces significant oxidative stress in Schwann cells by inhibiting the expression of the anti-oxidative protein DJ-1, leading to a decrease in Schwann cell markers. We found that the anti-oxidant dihydromyricetin (DMY) reverses 5-Fu-induced Schwann cell death and oxidative stress and alleviates capecitabine-induced myelin abnormalities. Taken together, our data indicate that capecitabine induces peripheral myelin dysfunction by regulating DJ-1-mediated oxidative stress in Schwann cells and reveal DMY as a potential therapeutic strategy for capecitabine-induced peripheral neuropathy.


Assuntos
Flavonóis , Bainha de Mielina , Doenças do Sistema Nervoso Periférico , Camundongos , Animais , Bainha de Mielina/metabolismo , Capecitabina/metabolismo , Estresse Oxidativo , Doenças do Sistema Nervoso Periférico/metabolismo , Fluoruracila/toxicidade
2.
Ecotoxicol Environ Saf ; 278: 116465, 2024 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-38749198

RESUMO

5-Fluorouracil (5-FU), a chemotherapeutic drug used to treat a variety of cancers, can enter the environment through different routes, causing serious public health and environmental concerns. It has been reported that 5-FU exposure adversely affects male reproductive function, and its effects on this system cannot be avoided. In this study, using western blotting and quantitative polymerase chain reaction studies, we found that 5-FU promoted testicular injury by inducing oxidative stress, which was accompanied by the inhibition of nuclear factor erythroid 2-related factor 2/antioxidant response element signaling. Accumulation of reactive oxygen species (ROS) aggravated 5-FU-mediated mitochondrial dysfunction and apoptosis in murine cell lines and testes, indicating oxidative stress and mitochondrial-dependent apoptotic signaling play crucial roles in the damage of spermatogenic cells caused. N-Acetyl-L-cysteine, an antioxidant that scavenges intracellular ROS, protected spermatogenic cells from 5-FU-induced oxidative damage and mitochondrial dysfunction, revealing the important role of ROS in testicular dysfunction caused by 5-FU. We found that 5-FU exposure induces testicular cell apoptosis through ROS-mediated mitochondria pathway in mice. In summary, our findings revealed the reproductive toxicological effect of 5-FU on mice and its mechanism, provided basic data reference for adverse ecological and human health outcomes associated with 5-FU contamination or poisoning.


Assuntos
Apoptose , Dano ao DNA , Fluoruracila , Mitocôndrias , Estresse Oxidativo , Espécies Reativas de Oxigênio , Testículo , Animais , Masculino , Fluoruracila/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Camundongos , Testículo/efeitos dos fármacos , Testículo/patologia , Mitocôndrias/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Apoptose/efeitos dos fármacos , Reprodução/efeitos dos fármacos , Linhagem Celular
3.
Drug Dev Res ; 85(2): e22171, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38459752

RESUMO

5-Fluorouracil (5-FU), which is one of the most widely used chemotherapy drugs, has various side effects on the heart. Thymoquinone (TMQ), the main bioactive component of Nigella sativa, has antioxidant and protective effects against toxicity. In this study, we investigated the protective effect of thymoquinone against cardiotoxicity caused by 5-FU in vitro and in vivo models. H9C2 cells were exposed to 5-FU and TMQ, and cell viability was evaluated in their presence. Also, 25 male Wistar rats were divided into five control groups, 5-FU, 2.5, and 5 mg TMQ in nanoemulsion form (NTMQ) + 5-FU and 5 mg NTMQ. Cardiotoxicity was assessed through electrocardiography, cardiac enzymes, oxidative stress markers, and histopathology. 5-FU induced cytotoxicity in H9c2 cells, which improved dose-dependently with NTMQ cotreatment. 5-FU caused body weight loss, ECG changes (increased ST segment, prolonged QRS, and QTc), increased cardiac enzymes (aspartate aminotransferase [AST], creatine kinase-myocardial band [CK-MB], and lactate dehydrogenase [LDH]), oxidative stress (increased malondialdehyde, myeloperoxidase, nitric acid; decreased glutathione peroxidase enzyme activity), and histological damage such as necrosis, hyperemia, and tissue hyalinization in rats. NTMQ ameliorated these 5-FU-induced effects. Higher NTMQ dose showed greater protective effects. Thus, the results of our study indicate that NTMQ protects against 5-FU cardiotoxicity likely through antioxidant mechanisms. TMQ warrants further research as an adjuvant to alleviate 5-FU chemotherapy side effects.


Assuntos
Antioxidantes , Benzoquinonas , Cardiotoxicidade , Ratos , Masculino , Animais , Cardiotoxicidade/tratamento farmacológico , Cardiotoxicidade/etiologia , Cardiotoxicidade/prevenção & controle , Antioxidantes/farmacologia , Antioxidantes/metabolismo , Ratos Wistar , Fluoruracila/toxicidade , Estresse Oxidativo
4.
Beijing Da Xue Xue Bao Yi Xue Ban ; 56(2): 213-222, 2024 Apr 18.
Artigo em Zh | MEDLINE | ID: mdl-38595236

RESUMO

OBJECTIVE: To evaluate the developmental toxicity of Cry1Ab protein by studying its effects on cell proliferation and differentiation ability using a developmental toxicity assessment model based on embryonic stem-cell. METHODS: Cry1Ab protein was tested in seven dose groups (31.25, 62.50, 125.00, 250.00, 320.00, 1 000.00, and 2 000.00 µg/L) on mouse embryonic stem cells D3 (ES-D3) and 3T3 mouse fibroblast cells, with 5-fluorouracil (5-FU) used as the positive control and phosphate buffer saline (PBS) as the solvent control. Cell viability was detected by CCK-8 assay to calculate the 50% inhibitory concentration (IC50) of the test substance for different cells. Additionally, Cry1Ab protein was tested in five dose groups (125.00, 250.00, 320.00, 1 000.00, and 2 000.00 µg/L) on ES-D3 cells, with PBS as the solvent control and 5-FU used for model validation. After cell treatment, cardiac differentiation was induced using the embryonic bodies (EBs) culture method. The growth of EBs was observed under a microscope, and their diameters on the third and fifth days were measured. The proportion of EBs differentiating into beating cardiomyocytes was recorded, and the 50% inhibition concentration of differentiation (ID50) was calculated. Based on a developmental toxicity discrimination function, the developmental toxicity of the test substances was classified. Furthermore, at the end of the culture period, mRNA expression levels of cardiac differentiation-related markers (Oct3/4, GATA-4, Nkx2.5, and ß-MHC) were quantitatively detected using real-time quantitative polymerase chain reaction (qPCR) in the collected EBs samples. RESULTS: The IC50 of 5-FU was determined as 46.37 µg/L in 3T3 cells and 32.67 µg/L in ES-D3 cells, while the ID50 in ES-D3 cells was 21.28 µg/L. According to the discrimination function results, 5-FU was classified as a strong embryotoxic substance. There were no statistically significant differences in cell viability between different concentrations of Cry1Ab protein treatment groups and the control group in both 3T3 cells and ES-D3 cells (P>0.05). Moreover, there were no statistically significant differences in the diameter of EBs on the third and fifth days, as well as their morphology, between the Cry1Ab protein treatment groups and the control group (P>0.05). The cardiac differentiation rate showed no statistically significant differences between different concentrations of Cry1Ab protein treatment groups and the control group (P>0.05). 5-FU significantly reduced the mRNA expression levels of ß-MHC, Nkx2.5, and GATA-4 (P < 0.05), showing a dose-dependent trend (P < 0.05), while the mRNA expression levels of the pluripotency-associated marker Oct3/4 exhibited an increasing trend (P < 0.05). However, there were no statistically significant differences in the mRNA expression levels of mature cardiac marker ß-MHC, early cardiac differentiation marker Nkx2.5 and GATA-4, and pluripotency-associated marker Oct3/4 between the Cry1Ab protein treatment groups and the control group (P>0.05). CONCLUSION: No developmental toxicity of Cry1Ab protein at concentrations ranging from 31.25 to 2 000.00 µg/L was observed in this experimental model.


Assuntos
Células-Tronco Embrionárias , Miócitos Cardíacos , Animais , Camundongos , Células-Tronco Embrionárias/metabolismo , Diferenciação Celular , Miócitos Cardíacos/metabolismo , Fluoruracila/toxicidade , RNA Mensageiro/metabolismo , Solventes/metabolismo , Solventes/farmacologia
5.
Curr Drug Metab ; 25(2): 91-95, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38504562

RESUMO

BACKGROUND: Fluoropyrimidine-induced toxicity is a main limitation of therapy. Currently, polymorphisms in the DPYD gene, which encodes the 5-FU activation enzyme dihydropyrimidine dehydrogenase (DPD), are used to adjust the dosage and prevent toxicity. Despite the predictive value of DPYD genotyping, a great proportion of fluoropyrimidine toxicity cannot be solely explained by DPYD variations. OBJECTIVE: We herein summarize additional sources of DPD enzyme activity variability, spanning from epigenetic regulation of DPYD expression, factors potentially inducing protein modifications, as well as drug-enzyme interactions that contribute to fluoropyrimidine toxicity. RESULTS: While seminal in vitro studies provided evidence that DPYD promoter methylation downregulates DPD expression, the association of DPYD methylation with fluoropyrimidine toxicity was not replicated in clinical studies. Different non-coding RNA molecules, such as microRNA, piwi-RNAs, circular-RNAs and long non-coding RNAs, are involved in post-transcriptional DPYD regulation. DPD protein modifications and environmental factors affecting enzyme activity may also add a proportion to the pooled variability of DPD enzyme activity. Lastly, DPD-drug interactions are common in therapeutics, with the most well-characterized paradigm the withdrawal of sorivudine due to fluoropyrimidine toxicity deaths in 5-FU treated cancer patients; a mechanism involving DPD severe inhibition. CONCLUSIONS: DPYD polymorphisms are the main source of DPD variability. A study on DPYD epigenetics (both transcriptionally and post-transcriptionally) holds promise to provide insights into molecular pathways of fluoropyrimidine toxicity. Additional post-translational DPD modifications, as well as DPD inhibition by other drugs, may explain a proportion of enzyme activity variability. Therefore, there is still a lot we can learn about the DPYD/DPD fluoropyrimidine-induced toxicity machinery.


Assuntos
Di-Hidrouracila Desidrogenase (NADP) , Humanos , Di-Hidrouracila Desidrogenase (NADP)/genética , Di-Hidrouracila Desidrogenase (NADP)/metabolismo , Animais , Antimetabólitos Antineoplásicos/toxicidade , Antimetabólitos Antineoplásicos/efeitos adversos , Fluoruracila/toxicidade , Fluoruracila/efeitos adversos , Epigênese Genética/efeitos dos fármacos , Polimorfismo Genético , Pirimidinas/toxicidade
6.
J Ethnopharmacol ; 326: 117988, 2024 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-38428657

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Perioperative or postoperative adjuvant chemotherapy based on 5-fluorouracil (5-FU) is a common first-line adjuvant therapy for gastric cancer (GC). However, drug resistance and the side effects of 5-FU have reduced its efficacy. Among these side effects, gastrointestinal (GI) toxicity is one of the most common. Xianglian Pill (XLP) is a Chinese patent medicine that is commonly used for the treatment of diarrhoea. It can reduce inflammation and has a protective effect on the intestinal mucosa. Recent studies have shown that many components of XLP can inhibite tumor cell growth. However, the therapeutic effect of XLP in combination with 5-FU on GC is unclear. AIM OF THE STUDY: To investigate whether the combination of XLP and 5-FU can enhance anti-GC activity while reducing GI toxicity. MATERIALS AND METHODS: XLP was administered orally during intraperitoneal injection of 5-FU in GC mice model. Mice were continuously monitored for diarrhea and xenograft tumor growth. After 2 weeks, the mice were sacrificed and serum was collected to determine interleukin-6 levels. Pathological changes, the expression of pro-inflammatory factors and p38 mitogen-activated protein kinase (MAPK) in GI tissue were determined by Western blot analysis. Pathological changes, apoptosis levels and p38 MAPK expression levels in xenograft tissues were also determined. RESULTS: The results showed that XLP could alleviate GI mucosal injury caused by 5-FU, alleviated diarrhea, and inhibited the expression of nuclear factor (NF)-κB and myeloid differentiation primary response-88. Besides, XLP could promote the 5-FU-induced apoptosis of GC cells and enhance the inhibitory effect of 5-FU on tumor xenografts. Further study showed that XLP administration could regulate the expression of p38 MAPK. CONCLUSIONS: XLP in combination with 5-FU could alleviate its GI side effects and enhance its inhibitory effect on xenograft tumor. Moreover, these effects were found to be related to the regulation of the p38 MAPK/NF-κB pathway.


Assuntos
Medicamentos de Ervas Chinesas , Fluoruracila , Neoplasias Gástricas , Humanos , Camundongos , Animais , Fluoruracila/toxicidade , Neoplasias Gástricas/tratamento farmacológico , NF-kappa B/metabolismo , Sistema de Sinalização das MAP Quinases , Diarreia/induzido quimicamente , Diarreia/tratamento farmacológico , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
7.
Eur Rev Med Pharmacol Sci ; 28(1): 144-154, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38235866

RESUMO

OBJECTIVE: Numerous cancers are treated with the chemotherapy drugs cyclophosphamide (CP), methotrexate (MT), and fluorouracil (FU). However, it should be noted that neurotoxicity is a possible side effect of chemotherapy. The pharmaceutical agent metformin (MTF) is used to control type 2 diabetes. The administration of MTF has been documented to exhibit a reduction in specific toxic effects associated with chemotherapy. The primary purpose of this research was to examine whether MTF could mitigate the neurotoxicity brought on by cranial magnetic field (CMF). MATERIALS AND METHODS: A cohort of forty male rats was divided into four distinct groups, with ten animals in each. We classified them as either saline, MTF, CMF, or CMF+MTF. The rats in the experiment group received two doses of CMF via intraperitoneal injection and were also given MTF in their drinking water at a concentration of 2.5 mg/mL on a daily basis. Brain tissue was obtained for ELISA of Bax, Bcl-2, and caspase-3 expression, as well as to determine NMDA and AMPA receptor mRNA expression by real-time polymerase chain reaction (RT-PCR) analysis. RESULTS: Expression of AMPAR, NMDAR, Bax, Bcl-2, and caspase-3 was not notably different between the saline and MTF groups. In contrast, mRNA expression for AMPAR, NMDAR, Bax, and caspase-3 was notably upregulated in the CMF group, while Bcl-2 was downregulated. The co-administration of MTF and CMF did not mitigate these side effects. CONCLUSIONS: neurotoxicity was induced in rats by CMF treatment, but the elevation of the glutamatergic system and the elevation of apoptotic proteins were not prevented by the MTF co-treatment.


Assuntos
Diabetes Mellitus Tipo 2 , Metformina , Humanos , Ratos , Masculino , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Proteína X Associada a bcl-2/genética , Diabetes Mellitus Tipo 2/tratamento farmacológico , Proteínas Proto-Oncogênicas c-bcl-2/genética , Ciclofosfamida , Fluoruracila/toxicidade , Metotrexato , RNA Mensageiro , Metformina/farmacologia
8.
Basic Clin Pharmacol Toxicol ; 134(3): 397-411, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38129993

RESUMO

Nephrotoxicity and hepatotoxicity include increased oxidative stress and apoptosis; as a result, liver and kidney damage are related to its pathogenesis. These are significant side effects caused in cancer patients treated with 5-FU. In the research, 25 rats were divided into five groups, including control, 5-FU and 5-FU + 2.5, 5 and 10 mg/kg melatonin (MEL), and the protective impact of MEL against 5-FU-induced hepatorenal damage in rats was investigated. 5-FU caused significant harm, resulting in severe renal failure and histopathological changes. It also increased BUN, creatinine and hepatic function markers levels while decreasing superoxide dismutase and glutathione peroxidase activity. Additionally, 5-FU led to a notable increase in malondialdehyde content. However, MEL co-administration to rats reversed most biochemical and histologic effects. In the control and MEL + 5-FU groups, the values were comparable. The doses of MEL treatment had a significant positive impact on 5-FU-induced oxidative stress, apoptosis, lipid peroxidation and kidney damage. Our data concluded that MEL has an ameliorative effect on hepatorenal damage caused by 5-FU.


Assuntos
Nefropatias , Melatonina , Humanos , Ratos , Animais , Melatonina/farmacologia , Melatonina/uso terapêutico , Fluoruracila/toxicidade , Fígado , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Antioxidantes/metabolismo , Rim , Estresse Oxidativo , Nefropatias/tratamento farmacológico , Superóxido Dismutase/metabolismo
9.
PeerJ ; 12: e17608, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38978756

RESUMO

According to our preliminary study, melatonin and its N-amide derivatives (N-(2-(1-4-bromobenzoyl-5-methoxy-1H-indol-3-yl)ethyl)acetamide (BBM) and 4-bromo-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)benzamide (EBM)) inhibited the marker of acute inflammation in tests in vitro and in vivo. The anti-inflammatory agent is intended for the prevention and treatment of chemotherapy-induced toxicity. In this study aimed to evaluate the effect of melatonin and its derivatives on mechanisms related to chemotherapy-induced oral mucositis by in vitro ROS and 5-FU-induced human keratinocyte cells as well as in vivo oral mucositis model. In in vitro H2O2-induced HaCaT cells, BBM had the highest level of protection (34.57%) at a concentration 50 µM, followed by EBM (26.41%), and melatonin (7.9%). BBM also protected cells against 5-FU-induced to 37.69-27.25% at 12.5-100 µM while EBM was 36.93-29.33% and melatonin was 22.5-11.39%. In in vivo 5-FU-induced oral mucositis in mice, melatonin, BBM, and EBM gel formulations protected tissue damage from 5-FU similar to the standard compound, benzydamine. Moreover, the weight of mice and food consumption recovered more quickly in the BBM group. These findings suggested that it was possible to develop BBM and EBM as new therapeutic agents for the treatment of oral mucositis.


Assuntos
Melatonina , Estomatite , Melatonina/farmacologia , Melatonina/uso terapêutico , Estomatite/induzido quimicamente , Estomatite/tratamento farmacológico , Estomatite/prevenção & controle , Estomatite/patologia , Animais , Humanos , Camundongos , Queratinócitos/efeitos dos fármacos , Fluoruracila/efeitos adversos , Fluoruracila/toxicidade , Masculino , Espécies Reativas de Oxigênio/metabolismo , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Antioxidantes/farmacologia
10.
Function (Oxf) ; 5(3): zqae011, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38706958

RESUMO

Thanks to recent progress in cancer research, most children treated for cancer survive into adulthood. Nevertheless, the long-term consequences of anticancer agents are understudied, especially in the pediatric population. We and others have shown that routinely administered chemotherapeutics drive musculoskeletal alterations, which contribute to increased treatment-related toxicity and long-term morbidity. Yet, the nature and scope of these enduring musculoskeletal defects following anticancer treatments and whether they can potentially impact growth and quality of life in young individuals remain to be elucidated. Here, we aimed at investigating the persistent musculoskeletal consequences of chemotherapy in young (pediatric) mice. Four-week-old male mice were administered a combination of 5-FU, leucovorin, irinotecan (a.k.a., Folfiri) or the vehicle for up to 5 wk. At time of sacrifice, skeletal muscle, bones, and other tissues were collected, processed, and stored for further analyses. In another set of experiments, chemotherapy-treated mice were monitored for up to 4 wk after cessation of treatment. Overall, the growth rate was significantly slower in the chemotherapy-treated animals, resulting in diminished lean and fat mass, as well as significantly smaller skeletal muscles. Interestingly, 4 wk after cessation of the treatment, the animals exposed to chemotherapy showed persistent musculoskeletal defects, including muscle innervation deficits and abnormal mitochondrial homeostasis. Altogether, our data support that anticancer treatments may lead to long-lasting musculoskeletal complications in actively growing pediatric mice and support the need for further studies to determine the mechanisms responsible for these complications, so that new therapies to prevent or diminish chemotherapy-related toxicities can be identified.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Camptotecina/análogos & derivados , Animais , Camundongos , Masculino , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Músculo Esquelético/efeitos dos fármacos , Irinotecano/efeitos adversos , Fluoruracila/efeitos adversos , Fluoruracila/toxicidade , Leucovorina , Camptotecina/efeitos adversos , Camptotecina/toxicidade , Antineoplásicos/efeitos adversos , Antineoplásicos/toxicidade , Camundongos Endogâmicos C57BL
11.
Mol Neurobiol ; 61(9): 6189-6199, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38285286

RESUMO

Primary cilia are crucial for neurogenesis, and cilium-related genes are involved in the closure of neural tubes. Inositol polyphosphate-5-phosphatase (Inpp5e) was enriched in primary cilia and closely related to the occurrence of neural tube defects (NTDs). However, the role of Inpp5e in the development of NTDs is not well-known. To investigate whether Inpp5e gene is associated with the neural tube closure, we established a mouse model of NTDs by 5-fluorouracil (5-FU) exposure at gestational day 7.5 (GD7.5). The Inpp5e knockdown (Inpp5e-/-) mouse embryonic stem cells (mESCs) were produced by CRISPR/Cas9 system. The expressions of Inpp5e and other cilium-related genes including intraflagellar transport 80 (Ift80), McKusick-Kaufman syndrome (Mkks), and Kirsten rat sarcoma viral oncogene homolog (Kras) were determined, utilizing quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), western blot, PCR array, and immunofluorescence staining. The result showed that the incidence of NTDs was 37.10% (23 NTDs/62 total embryos) and significantly higher than that in the control group (P < 0.001). The neuroepithelial cells of neural tubes were obviously disarranged in NTD embryos. The mRNA and protein levels of Inpp5e, Ift80, Mkks, and Kras were significantly decreased in NTD embryonic brain tissues, compared to the control (P < 0.05). Knockdown of the Inpp5e (Inpp5e-/-) reduced the expressions of Ift80, Mkks, and Kras in mESCs. Furthermore, the levels of α-tubulin were significantly reduced in NTD embryonic neural tissue and Inpp5e-/- mESCs. These results suggested that maternal 5-FU exposure inhibited the expression of Inpp5e, which resulted in the downregulation of cilium-related genes (Ift80, Mkks, and Kras), leading to the impairment of primary cilium development, and ultimately disrupted the neural tube closure.


Assuntos
Cílios , Fluoruracila , Defeitos do Tubo Neural , Animais , Fluoruracila/farmacologia , Fluoruracila/toxicidade , Cílios/metabolismo , Cílios/efeitos dos fármacos , Defeitos do Tubo Neural/genética , Defeitos do Tubo Neural/induzido quimicamente , Feminino , Camundongos , Monoéster Fosfórico Hidrolases/genética , Monoéster Fosfórico Hidrolases/metabolismo , Gravidez , Células-Tronco Embrionárias Murinas/metabolismo , Células-Tronco Embrionárias Murinas/efeitos dos fármacos
12.
Int J Immunopathol Pharmacol ; 38: 3946320241227099, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38207276

RESUMO

INTRODUCTION: The clinical use of 5-fluorouracil (5-FU), a routinely used chemotherapy medication, has a deleterious impact on the liver. Therefore, it is necessary to find a less harmful alternative to minimize liver damage. This study was designed to see how 5-fluorouracil nanogel influenced 5-FU-induced liver damage in rats. METHODS: To induce liver damage, male albino rats were injected intraperitoneally with 5-FU (12.5 mg/kg) three doses/week for 1 month. The histopathological examination together with measuring the activities of serum alanine and aspartate aminotransferase enzymes (ALT and AST) were used to evaluate the severity of liver damage besides, hepatic oxidative stress and antioxidant markers were also measured. The hepatic gene expression of heme oxygenase-1 (HO-1), nuclear factor erythroid 2-related factor 2 (Nrf2) and its inhibitor Kelch-like ECH-associated protein-1(Keap-1) in addition to hepatic inflammatory mediators including tumor necrosis factor-α (TNF- α) and interleukins (IL-1ß, IL-6) were detected. RESULTS: 5-Fu nanogel effectively attenuated 5-FU-induced liver injury by improving the hepatic structure and function (ALT and AST) besides the suppression of the hepatic inflammatory mediators (TNF- α, IL-1ß and IL-6). Additionally, 5-FU nanogel alleviated the impaired redox status and restored the antioxidant system via maintaining the cellular homeostasis Keap-1/Nrf2/HO-1 pathway. CONCLUSION: Consequently, 5-Fu nanogel exhibited lower liver toxicity compared to 5-FU, likely due to the alleviation of hepatic inflammation and the regulation of the cellular redox pathway.


Assuntos
Antioxidantes , Doença Hepática Induzida por Substâncias e Drogas , Polietilenoglicóis , Polietilenoimina , Ratos , Masculino , Animais , Antioxidantes/metabolismo , Fluoruracila/toxicidade , Fator 2 Relacionado a NF-E2 , Interleucina-6/metabolismo , Nanogéis , Fígado , Estresse Oxidativo , Doença Hepática Induzida por Substâncias e Drogas/patologia , Mediadores da Inflamação/metabolismo
13.
Sci Rep ; 14(1): 15730, 2024 07 08.
Artigo em Inglês | MEDLINE | ID: mdl-38977864

RESUMO

5-Fluorouracil (5-Fu) is a basic drug that is used to treat colorectal cancer. Patients who receive 5-Fu chemotherapy often experience side effects that affect the digestive system, such as intestinal injury and diarrhoea, which significantly affect patient compliance with anticancer treatment and quality of life. Therefore, identifying approaches to treat or prevent these side effects is urgent. Dasabuvir (DSV) is a hepatitis C virus inhibitor, but its impact on 5-Fu-induced intestinal injury remains unknown. Our study investigated the effects of DSV on 5-Fu-induced intestinal injury in HUVECs, HIECs and male BALB/c mice. We found that 5-Fu caused intestinal damage by inducing senescence, increasing inflammatory factor expression, and generating oxidative stress. Compared with 5-Fu treatment alone, DSV inhibited senescence by reducing senescence-ß-galactosidase (SA-ß-gal) activity, the senescence-associated secretory phenotype (SASP, including IL-1, IL-6, and TNF-α) and senescence marker expression levels (p16, p21, and p53). Moreover, the anti-senescence effect of DSV was achieved by inhibiting the mTOR signaling pathway. DSV increased antioxidant enzyme levels and alleviated intestinal tissue injury in mice. In addition, DSV suppressed the 5-Fu-induced increase the diarrhoea scores and ameliorated the weight loss, food intake and water intake of the mice. Overall, this study indicated that DSV could be used to treat chemotherapy-induced intestinal damage.


Assuntos
Anti-Inflamatórios , Senescência Celular , Fluoruracila , Camundongos Endogâmicos BALB C , Animais , Fluoruracila/efeitos adversos , Fluoruracila/toxicidade , Humanos , Masculino , Camundongos , Senescência Celular/efeitos dos fármacos , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Células Endoteliais da Veia Umbilical Humana , Estresse Oxidativo/efeitos dos fármacos , Serina-Treonina Quinases TOR/metabolismo , Transdução de Sinais/efeitos dos fármacos , Intestinos/efeitos dos fármacos , Intestinos/patologia
14.
Aging (Albany NY) ; 16(7): 5916-5928, 2024 03 25.
Artigo em Inglês | MEDLINE | ID: mdl-38536006

RESUMO

BACKGROUND: Fluorouracil (5-FU) might produce serious cardiac toxic reactions. miRNA-199a-5p is a miRNA primarily expressed in myocardial cells and has a protective effect on vascular endothelium. Under hypoxia stress, the expression level of miRNA-199a-5p was significantly downregulated and is closely related to cardiovascular events such as coronary heart disease, heart failure, and hypertension. We explored whether 5-FU activates the endoplasmic reticulum stress ATF6 pathway by regulating the expression of miRNA-199a-5p in cardiac toxicity. METHODS: This project established a model of primary cardiomyocytes derived from neonatal rats and treated them with 5-FU in vitro. The expression of miRNA-199a-5p and its regulation were explored in vitro and in vivo. RESULTS: 5-FU decreases the expression of miRNA-199a-5p in cardiomyocytes, activates the endoplasmic reticulum stress ATF6 pathway, and increases the expression of GRP78 and ATF6, affecting the function of cardiomyocytes, and induces cardiac toxicity. The rescue assay further confirmed that miRNA-199a-5p supplementation can reduce the cardiotoxicity caused by 5-FU, and its protective effect on cardiomyocytes depends on the downregulation of the endoplasmic reticulum ATF6 signaling pathway. CONCLUSIONS: 5-FU can down-regulate expression of miRNA-199a-5p, then activate the endoplasmic reticulum stress ATF6 pathway, increase the expression of GRP78 and ATF6, affect the function of cardiomyocytes, and induce cardiac toxicity.


Assuntos
Fator 6 Ativador da Transcrição , Cardiotoxicidade , Regulação para Baixo , Chaperona BiP do Retículo Endoplasmático , Estresse do Retículo Endoplasmático , Fluoruracila , MicroRNAs , Miócitos Cardíacos , Transdução de Sinais , Animais , Fator 6 Ativador da Transcrição/metabolismo , Fator 6 Ativador da Transcrição/genética , MicroRNAs/metabolismo , MicroRNAs/genética , Ratos , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/metabolismo , Transdução de Sinais/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Fluoruracila/toxicidade , Fluoruracila/efeitos adversos , Cardiotoxicidade/metabolismo , Cardiotoxicidade/genética , Cardiotoxicidade/etiologia , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Células Cultivadas , Ratos Sprague-Dawley , Masculino
15.
Autops. Case Rep ; 8(4): e2018049, Oct.-Dec. 2018. ilus, graf
Artigo em Inglês | LILACS | ID: biblio-986574

RESUMO

5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy.


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Deficiência da Di-Hidropirimidina Desidrogenase/patologia , Fluoruracila/toxicidade , Neoplasias de Cabeça e Pescoço , Autopsia , Evolução Fatal , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Deficiência da Di-Hidropirimidina Desidrogenase/tratamento farmacológico , Fluoruracila/uso terapêutico , Linfonodos
16.
Pharm. care Esp ; 18(6): 241-250, 2016. tab, graf
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-158601

RESUMO

Introducción: Las revisiones del 2007 a la farmacopea americana vigente en todo el hemisferio occidental (USP capítulo 797) incluyen una sección sobre el manejo de fármacos peligrosos como preparaciones magistrales estériles, donde se recomienda el muestreo ambiental para detectar trazas de fármacos peligrosos no contenidos, afirmando que esta medida de calidad debe llevarse a cabo de forma rutinaria. Objetivo: Determinar la tasa de contaminación con agentes citotóxicos en las áreas de trabajo de tres instituciones hospitalarias de Colombia. Material y métodos: Estudio descriptivo, prospectivo, transversal. Se recolectaron muestras de 18 áreas evaluando simultáneamente la presencia de tres fármacos que han sido históricamente usados como trazadores de contaminación química: Ciclofosfamida, 5-Fluorouracilo y Carboplatino. Se evalúan superficies de áreas de preparación (cabina de seguridad biológica-CSB o aislador de barrera-AB), alistamiento y administración de medicamentos oncológicos incluyendo áreas comunes a la central de mezclas y la sala de administración de medicamentos oncológicos. Resultados: En el departamento de enfermería y farmacia existe contaminación química debido a los medicamentos citostáticos. En enfermería la contaminación se dio más debido a Carboplatino mientras que en el área de central de mezclas, el fármaco que más detectado fue 5-fluoruracilo. La comparación entre ambos departamentos permite evidenciar que la mayor tasa de contaminación se ha encontrado en farmacia. El principio activo más detectado fue 5-fluoruracilo. Conclusión: Se recomienda que las instituciones revisen los estándares para la preparación y administración de fármacos peligrosos a la luz de la normatividad mundial (USP, ASHP, ISOPP) en aspectos como la política y el procedimiento actual, controles de ingeniería, procedimientos de limpieza, manipulación de los viales del fabricante, evaluación de la CSB o AB, capacitación y educación del personal tanto en las áreas de preparación y administración, uso de EPP adecuados, la incidencia de derrames recientes en el área de la farmacia o de preparación que podrían elevar los niveles de detección y la implementación de CSTD


Introduction: The reviews made in 2007 to the current American pharmacopoeia throughout the Western Hemisphere (USP Chapter 797) include a section about handling hazardous drugs as master sterile preparations. In this sense, environmental sampling is recommended to detect traces of dangerous and not contained drugs. It is stated this quality measure should be carried out routinely. Objective: To determine the rate of contamination with cytotoxic agents in the working areas of three hospitals in Colombia. Material and Methods: It was carried out a descriptive, prospective and cross-sectional study. Samples were collected simultaneously from 18 areas. It was evaluated the presence of three drugs that have been historically used as tracers of chemical contamination: Cyclophosphamide, 5-fluorouracil and carboplatin. The surface of preparation areas (biological safety cabinet or isolator CSB-barrier-AB), enlistment areas and the ones of cancer drugs administration including common areas of the central mixing and living areas of oncology drugs administration were evaluated. Results: In the department of nursing and pharmacy exists chemical contamination caused by cytostatic drugs. In nursing pollution was mainly related to carboplatin while in the central mixing area, the most detected document was 5-fluorouracil. The comparison between both departments shows that the highest rate of contamination was found in pharmacy. The most detected active substance was 5-fluorouracil. Conclusion: It is recommended that institutions review the standards for the preparation and administration of hazardous drugs in the light of global standards (USP, ASHP, Isopp) in areas such as politics and the current procedure, engineering controls, cleaning procedures, handling manufacturer’s vials, assessment of CSB or AB, training and education of the staff both, in the areas of preparation and administration, use of appropriate PPE, the incidence of recent spills in the pharmacy or preparation area that could raise detection levels and the implementation of CSTD


Assuntos
Humanos , Citotoxinas/toxicidade , Fluoruracila/toxicidade , Carboplatina/toxicidade , Poluição Ambiental/análise , Ciclofosfamida/toxicidade , Exposição Ocupacional , Exposição a Produtos Químicos , Serviço de Farmácia Hospitalar/estatística & dados numéricos , Serviço Hospitalar de Enfermagem/estatística & dados numéricos , Estudos Prospectivos
17.
Braz. dent. j ; 25(6): 565-570, Nov-Dec/2014. graf
Artigo em Inglês | LILACS | ID: lil-732255

RESUMO

The passive fit of implant-supported dentures is fundamental to the rehabilitation success due the absence of the periodontal ligament in osseointegrated implants. Many techniques to obtain passive fit have been reported in the literature, some inaccessible for the clinicians and dental laboratories. This case report presents a technique to fabricate fixed complete dentures aiming at obtain passive fit with reduced time and cost, but without demerit for the aesthetics, function and longevity. A 40-year-old woman was referred for treatment presenting some teeth in the maxilla and an edentulous mandible, reporting eating problems related to instability and little retention of the mandibular complete denture. Treatment based on the reverse planning was performed to guide the rehabilitation with a complete mandibular fixed complete denture and maxillary occlusal plane adjustment. The framework of the fixed complete denture was manufactured luting a cast metal bar above the prepared titanium cylinder abutments using resin cement. The aim of this technique was to obtain a fixed complete denture with passive fit presenting positive esthetic and functional outcomes after 2 years of follow-up.


A adaptação passiva de próteses implantossuportadas é fundamental para o sucesso da reabilitação devido à inexistência de ligamento periodontal em implantes osseointegrados. Inúmeras técnicas de confecção da infraestrutura destas próteses tem sido relatadas na literatura, algumas inacessíveis para os clínicos e laboratórios de prótese. Este relato de caso apresenta uma técnica para confecção de próteses totais fixas visando obtenção de adaptação passiva com tempo e custo reduzido, porém sem demérito à estética, função e longevidade. Uma paciente de 40 anos se apresentou para tratamento apresentando alguns dentes na maxila e mandíbula edêntula, relatando dificuldades na mastigação relacionados a instabilidade e falta de retenção da prótese total inferior. Foi realizado um planejamento reverso para orientar a reabilitação com prótese total mandibular fixa e adequação do plano oclusal da maxila. A infraestrutura da prótese total fixa foi confeccionada pela cimentação de uma barra metálica em cilindros de titânio preparados com cimento resinoso. O objetivo desta técnica foi obter uma prótese total fixa com adaptação passiva apresentando resultados positivos em termos de estética e função após 2 anos de acompanhamento.


Assuntos
Animais , Feminino , Masculino , Camundongos , Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Floxuridina/uso terapêutico , Fluoruracila/uso terapêutico , Adenocarcinoma/patologia , Adenocarcinoma/radioterapia , Medula Óssea/patologia , Terapia Combinada , Neoplasias do Colo/patologia , Neoplasias do Colo/radioterapia , Floxuridina/administração & dosagem , Floxuridina/toxicidade , Fluoruracila/administração & dosagem , Fluoruracila/toxicidade , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos DBA , Baço/patologia , Timo/patologia , Aumento de Peso
18.
Rev. bras. enferm ; 67(6): 987-993, Nov-Dec/2014. tab, graf
Artigo em Português | LILACS, BDENF - enfermagem (Brasil) | ID: lil-732824

RESUMO

Objetivo: Identificar na literatura indicações e controvérsias do ATP bioluminescência para avaliação da efetividade da limpeza de superfícies em estabelecimentos de saúde. Método: Revisão integrativa da literatura, entre 2000 e 2012, nas bases de dados MEDLINE, LILACS, Science Direct, SCOPUS e Isi Web of Knowledge. Resultados: Selecionou-se para esta revisão 15 artigos. O ATP bioluminescência foi apontado como importante recurso educacional e método complementar à inspeção visual e às análises microbiológicas na avaliação da efetividade da limpeza. A impossibilidade de indicar a contaminação da superfície por micro-organismos viáveis, a interferência por substâncias químicas e a dificuldade de interpretação dos resultados constituem as principais controvérsias para o uso deste nos serviços de saúde. Conclusão: Apesar de constituir importante recurso na avaliação da limpeza de superfícies, mais estudos são necessários para incorporação efetiva do método nos serviços de saúde. .


Objective: To identify indications and controversies in the literature of the use of ATP bioluminescence to evaluate the effectiveness of surface cleaning in healthcare facilities. Method: Integrative literature review between 2000 and 2012 in the following databases: MEDLINE, LILACS, Science Direct, SCOPUS and Isi Web of Knowledge. Results: were selected for this review 15 articles. The ATP bioluminescence was considered an important educational resource and complementary method to visual inspection and microbiological evaluation of the effectiveness of cleaning. The impossibility to indicate surface contamination by microorganisms, interference by chemicals and the difficulty of interpreting the results constitute the main controversies in the use of ATP in health services. Conclusion: Although this is an important resource in the evaluation of surface cleaning, more studies are necessary for effective incorporation of the method in health services. .


Objetivo: Identificar en la literatura las indicaciones y controversias sobre el uso de la bioluminiscencia ATP para evaluar la eficacia de la limpieza de superficies en los servicios de salud. Método: Revisión integrativa de la literatura, entre 2000 y 2012, en las siguientes bases de datos: MEDLINE, LILACS, Science Direct, SCOPUS e ISI Web of Knowledge. Resultados: Se seleccionaron para esta revisión 15 artículos. La bioluminiscencia del ATP se considera un importante recurso educativo y método complementario a la inspección visual y la análisis microbiológica de la evaluación de la efectividad de la limpieza. La imposibilidad de indicar contaminación de la superficie por los microorganismos, la interferencia por los productos químicos y la dificultad de interpretar los resultados constituyen las principales controversias en la utilización de ATP en los servicios de salud. Conclusión: Aunque esto es un elemento importante en la evaluación de limpieza de superficies, se necesitan más estudios para incorporación eficaz del método en los servicios de salud. .


Assuntos
Animais , Masculino , Camundongos , Antineoplásicos/farmacologia , Desoxicitidina/análogos & derivados , Floxuridina/farmacologia , Intestinos/efeitos dos fármacos , Pró-Fármacos/farmacologia , Desoxicitidina/farmacologia , Floxuridina/metabolismo , Floxuridina/toxicidade , Fluoruracila/metabolismo , Fluoruracila/farmacologia , Fluoruracila/toxicidade , Camundongos Endogâmicos , Neoplasias Experimentais/tratamento farmacológico , Pró-Fármacos/toxicidade
19.
Arch. med. interna (Montevideo) ; 35(2): 37-47, jul. 2013. ilus
Artigo em Espanhol | LILACS | ID: lil-722865

RESUMO

La cardiotoxicidad por fármacos quimioterápicos es un efecto adverso frecuente y esperado. En este sentido se ha creado una especialización, la cardiooncología, que tiene como principal objetivo la prevención de estos efectos. La forma de expresión de este fenómeno es muy variada, pudiendo manifestarse como: insuficiencia cardíaca, hipertensión arterial, eventos coronarios agudos y/o trastornos del ritmo. La clave en la prevención está en la idividualización del riesgo cardiotóxico de cada paciente (en base a factores reconocidos como edad, sexo, irradiación mediastinal previa, tipo de fármaco, dosis acumulada, cardiopatía asociada previamente) y el riesgo potencial cardiotóxico de cada quimioterápico. En este sentido se han creado algoritmos de actuación fundamentados en la monitorización y el inicio de tratamiento precoz y oportuno de cada efecto, previniendo el mal mayor en cada paciente.


Assuntos
Humanos , Masculino , Feminino , Antineoplásicos/toxicidade , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Doenças Cardiovasculares/etiologia , Alquilantes , Anticorpos Monoclonais , Antineoplásicos Alquilantes/efeitos adversos , Antineoplásicos Alquilantes/toxicidade , Antineoplásicos/efeitos adversos , Antraciclinas/efeitos adversos , Antraciclinas/toxicidade , Fluoruracila/efeitos adversos , Fluoruracila/toxicidade , Inibidores de Proteínas Quinases , Toxoides/efeitos adversos , Toxoides/toxicidade
20.
Arq. gastroenterol ; 43(2): 94-101, abr. -jun. 2006.
Artigo em Português | LILACS | ID: lil-435251

RESUMO

RACIONAL: O câncer colorretal é a quarta causa de câncer no Brasil e o 5-fluourouracil uma das principais drogas usadas no tratamento adjuvante e paliativo dessa doença. A toxicidade da quimioterapia e as alterações de qualidade de vida, causadas pela própria doença e pelo tratamento, são motivo de muitos estudos. OBJETIVO: Avaliar nos doentes com câncer colorretal em tratamento quimioterápico, a toxicidade e possíveis alterações da qualidade de vida. MÉTODOS: Durante o período de março de 2001 a maio de 2003 no Ambulatório de Oncologia da Disciplina de Gastroenterologia Clínica da Universidade Federal de São Paulo, foram acompanhados 45 pacientes com câncer colorretal em tratamento quimioterápico adjuvante ou paliativo com 5-fluourouracil e ácido folínico durante seis ciclos. A toxicidade gastrointestinal e hematológica foi analisada utilizando-se as Recomendações para a Graduação da Toxicidade Aguda e Subaguda. Após o término de cada ciclo quimioterápico, os resultados foram anotados de acordo com os respectivos graus que variaram entre 0 e 4. A qualidade de vida foi pesquisada pelo questionário WHOQOL bref (World Health Organization Quality of Life) que consta de 26 questões e é composto por 4 domínios: físico, psicológico, relações sociais e meio ambiente, no início, no 3° e no 6° ciclo de tratamento. RESULTADOS: Entre os 45 pacientes, 28 eram do sexo masculino, a média de idade foi de 58,4 anos (34 a 79 anos). Segundo a classificação da União Internacional Contra o Câncer, 34 (75,6 por cento) eram estádio II ou III e 11 estádio IV (24,4 por cento). Quanto à localização, 64,4 por cento eram de cólon. Em 57,7 por cento a quimioterapia foi adjuvante e nos demais paliativa. As toxicidades mais comumente encontradas foram náuseas (42 por cento), diarréia (38 por cento) e neutropenia (15,7 por cento). Não houve diferença significante entre os graus de toxicidade nos diferentes ciclos, assim como entre os doentes em tratamento adjuvante ou paliativo. Quanto à qualidade de vida foram observadas alterações significantes nos domínios físico e psicológico quando comparadas a primeira com a segunda ou a primeira com a terceira aplicação do questionário. Não foi encontrada alteração da qualidade de vida entre os doentes em quimioterapia adjuvante quando comparada aos em tratamento paliativo. Independente da indicação terapêutica, a média dos escores de qualidade de vida diminuiu em relação aos domínios físico e social na terceira aplicação do teste. CONCLUSÃO: As toxicidades gastrointestinais foram mais freqüentes que as hematológicas com o esquema utilizado. A qualidade de vida diminuiu após o início da quimioterapia em relação à atividade física e psicológica. No estudo da média dos escores observou-se queda dos mesmos nos domínios físico e social. A análise do questionário não mostrou alteração de qualidade vida quando comparados os doentes em tratamento paliativo com os em adjuvância.


BACKGROUND: The colorectal cancer is the fourth cause of cancer in Brazil and 5-fluorouracil is the drug most commonly used in the adjuvant or palliative treatment of this disease. AIM - Evaluating in patients with colorectal cancer and chemotherapy, the toxicity and the quality of life. PATIENTS AND METHODS: From March 2001 and May 2003, 45 patients treated with colorectal cancer treated with 5-fluourouracil and folinic acid were followed closely during six cycles. The gastrointestinal and hematologic toxicity was analysed making use of the chart "Recommendations for the Graduation of Acute and Subacute Toxicity". After the end of each cycle of chemotherapy, the results were registered according to the respectives degrees that vary from 0 to 4. The quality of life was researched through the WHOQOL bref (World Health Organization Quality of Life) questionary that consists of 26 questions and 4 domains: physical, psychological, social relations and environmental, in the beginning, on the 3rd and 6th cycles of treatment. RESULTS: Among the 45 patients, 28 were male, the average age was 58.4 years old (from 34 to 79 years old). According to the International Union Against Cancer classification, 34 patients (75.6 percent) had tumors stage II or III and 11 had tumors stage IV (24.4 percent), 64.4 percent were in the colon. In 57.7 percent the chemotherapy was adjuvant and in the others palliative. The toxicities more commonly found were nauseas (42 percent), diarrhea (38 percent), and neutropenia (15.7 percent). There was no significant difference among the degrees of toxicity in the different cycles as well as among the patients in adjuvant or palliative treatment. Significant alterations was found among the quality of life in the physical and psychological domains when the 1st and the 2nd or the 1st and the 3rd application of the test were done. Alterations of the quality of life were also found in the social domain when the first evaluation was compared with the last one. There was no difference between the quality of life and the treatment.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Neoplasias Colorretais/tratamento farmacológico , Qualidade de Vida , Adenocarcinoma/psicologia , Adenocarcinoma/cirurgia , Antimetabólitos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/toxicidade , Quimioterapia Adjuvante , Neoplasias Colorretais/psicologia , Neoplasias Colorretais/cirurgia , Fluoruracila/administração & dosagem , Fluoruracila/toxicidade , Leucovorina/administração & dosagem , Leucovorina/toxicidade , Estadiamento de Neoplasias , Cuidados Paliativos , Prognóstico , Estudos Prospectivos , Fatores de Risco , Inquéritos e Questionários , Complexo Vitamínico B/administração & dosagem , Complexo Vitamínico B/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA